Media stories about MacroGenics (NASDAQ:MGNX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MacroGenics earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.7887611616075 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Several brokerages have weighed in on MGNX. Stifel Nicolaus reiterated a “buy” rating and issued a $34.00 price target on shares of MacroGenics in a report on Tuesday, September 12th. Cowen and Company reiterated a “buy” rating on shares of MacroGenics in a report on Friday, August 4th. ValuEngine downgraded MacroGenics from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. BidaskClub downgraded MacroGenics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 12th. Finally, Morgan Stanley cut their price target on MacroGenics from $22.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, August 7th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. MacroGenics has a consensus rating of “Hold” and a consensus target price of $30.30.
Shares of MacroGenics (MGNX) traded down 0.63% during mid-day trading on Thursday, hitting $17.24. 74,293 shares of the stock traded hands. The company’s market cap is $634.40 million. The stock has a 50-day moving average of $17.76 and a 200-day moving average of $18.18. MacroGenics has a 52 week low of $14.36 and a 52 week high of $31.85.
MacroGenics (NASDAQ:MGNX) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.09). MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The company had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $15.82 million. During the same quarter in the previous year, the company earned $1.12 EPS. The firm’s quarterly revenue was down 97.9% compared to the same quarter last year. Analysts anticipate that MacroGenics will post ($4.42) EPS for the current year.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
What are top analysts saying about MacroGenics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MacroGenics Inc. and related companies.